09 February 2017

MDxHealth Notice of Financial Year 2016 Results      

Conference call for analysts and investors to be held on 23 February 2017 at 15:00 CET

IRVINE, CA, and HERSTAL, BELGIUM – February 9, 2017 – MDxHealth SA (Euronext: MDXH.BR) or the “Company” today announced that it will release its full year results for the financial year ended 31 December 2016 on Thursday 23 February 2017.

To access the conference call, please dial one of the appropriate numbers below quoting the conference ID 69886101.

Belgium: +32 (0)81 70 00 61

The Netherlands: +31 (0)8000 235 091

UK: +44 (0)1452 55 55 66

US: +1 (0)8669 669 439

The presentation will be made available on the Investors section of the MDxHealth website shortly before the call and can be accessed at: http://mdxhealth.com/investors.

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled start timing.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. MDxHealth’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth

For more information: 

US: +1 949 812 6979
BE: +32 4 364 20 70


Consilium Strategic Communications (IR & PR)
Amber Fennell, Chris Welsh & Hendrik Thys
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

Back to previous page